Designing organic molecules as platforms for reversible charge-to-spin conversion with applications in chromophore optimisation and drug discovery
This project aims to explore reversible diradical formation in donor-acceptor organic molecules to enhance light-emitting materials and drug discovery through novel design criteria.
Projectdetails
Introduction
Chemistry and Biology are governed by molecules and how they interact. Crucially, what glues a molecule together are chemical bonds, made from atoms pairing all their electrons. Although preferred, this is not the only option: in the comparatively rare cases where a molecule presents unpaired electrons, it acquires a fascinating new status that transforms its chemical and biological properties, best described by the acutely apt name of radical.
Limitations of Current Methods
Despite the extraordinary toolset found in radical-bearing molecules, the rather demanding methods to radical formation currently available mean that only very specific molecular architectures can withstand them, inadvertently limiting the scope of their applicability.
Project Aim
The aim of this ERC project is to show that reversible diradical formation upon deprotonation is prevalent, and yet unexplored, in general donor-acceptor organic molecules and use this new knowledge to develop novel design criteria in light-emitting molecules and drug discovery.
Methodology
To achieve this unique aim, I will exploit a widespread structural pattern in a novel way, enabling a molecule to reversibly convert its charge and spin and become a diradical.
- I will first characterise how different molecular constituents (un)favour diradical formation on isolated molecules.
- I will then establish, for the first time, the role that diradicals play in defining the function of the numerous bioactive molecules sharing the proposed structural pattern.
Expected Outcomes
By exposing the overlooked diradical character in general families of deprotonated organic molecules, I will deliver transformative mechanistic understanding on:
i) the photo physical properties of fluorescent proteins and
ii) the reactivity of small molecule drugs, particularly a new class of covalent inhibitors.
Significance
The field of organic radicals sits at a critical crossroads between Chemistry and Biology, and as such, taking it a step forward has the potential to cross-pollinate research fields and reshape research frontiers.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.498.361 |
Totale projectbegroting | € 1.498.361 |
Tijdlijn
Startdatum | 1-6-2024 |
Einddatum | 31-5-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEApenvoerder
- ASOCIACION INSTITUTO DE INVESTIGACION SANITARIA BIOBIZKAIA
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Transforming Boron Chemistry By Exploring Boryl Radical ReactivityThis project aims to innovate organic chemistry by developing novel catalysis using boryl radicals for efficient C–B bond formation and new synthetic methods for complex molecules. | ERC Consolid... | € 1.999.250 | 2024 | Details |
Enhancing the Potential of Enzymatic Catalysis with LightPHOTOZYME aims to integrate photocatalysis, biocatalysis, and organocatalysis to sustainably produce chiral molecules through innovative photoenzymes and radical reactions. | ERC Advanced... | € 2.945.000 | 2024 | Details |
Radical and Radical-Polar Crossover Logic in Terpenoid SynthesisThis project aims to redefine terpenoid biogenesis by demonstrating the interplay of radical and polar reactivity, enabling sustainable synthesis of druggable natural products for medical applications. | ERC Consolid... | € 1.987.059 | 2022 | Details |
Strongly Polarized Carbon: Taming Fundamental Intermediates and Their ApplicationsCC-CHARGED aims to induce CC bond polarization to create stable, unexplored carbon compounds, enhancing organic synthesis and enabling new applications in chemistry and molecular editing. | ERC Starting... | € 1.499.960 | 2023 | Details |
SOMO-HOMO Inversion For chiral open-shell pi-conjUgated systeMsThis project aims to design stable chiral organic diradicals with inverted SOMO-HOMO levels to enhance optoelectronic devices' efficiency and enable advanced spin-filter applications. | ERC Starting... | € 1.744.065 | 2022 | Details |
Transforming Boron Chemistry By Exploring Boryl Radical Reactivity
This project aims to innovate organic chemistry by developing novel catalysis using boryl radicals for efficient C–B bond formation and new synthetic methods for complex molecules.
Enhancing the Potential of Enzymatic Catalysis with Light
PHOTOZYME aims to integrate photocatalysis, biocatalysis, and organocatalysis to sustainably produce chiral molecules through innovative photoenzymes and radical reactions.
Radical and Radical-Polar Crossover Logic in Terpenoid Synthesis
This project aims to redefine terpenoid biogenesis by demonstrating the interplay of radical and polar reactivity, enabling sustainable synthesis of druggable natural products for medical applications.
Strongly Polarized Carbon: Taming Fundamental Intermediates and Their Applications
CC-CHARGED aims to induce CC bond polarization to create stable, unexplored carbon compounds, enhancing organic synthesis and enabling new applications in chemistry and molecular editing.
SOMO-HOMO Inversion For chiral open-shell pi-conjUgated systeMs
This project aims to design stable chiral organic diradicals with inverted SOMO-HOMO levels to enhance optoelectronic devices' efficiency and enable advanced spin-filter applications.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
SUPRAMOLECULAR AGENTS AS RADIOTHERANOSTIC DRUGSSMARTdrugs aims to revolutionize cancer treatment by developing supramolecular radiotheranostics that integrate diagnostics and therapy for targeted drug delivery. | EIC Pathfinder | € 2.135.087 | 2024 | Details |
SUPRAMOLECULAR AGENTS AS RADIOTHERANOSTIC DRUGS
SMARTdrugs aims to revolutionize cancer treatment by developing supramolecular radiotheranostics that integrate diagnostics and therapy for targeted drug delivery.